BR0115055A - Terapia de combinação compreendendo agentes anticonvulsantes e antidiabéticos - Google Patents
Terapia de combinação compreendendo agentes anticonvulsantes e antidiabéticosInfo
- Publication number
- BR0115055A BR0115055A BR0115055-3A BR0115055A BR0115055A BR 0115055 A BR0115055 A BR 0115055A BR 0115055 A BR0115055 A BR 0115055A BR 0115055 A BR0115055 A BR 0115055A
- Authority
- BR
- Brazil
- Prior art keywords
- combination therapy
- antidiabetic agents
- anticonvulsant
- antidiabetic
- agents
- Prior art date
Links
- 229940125708 antidiabetic agent Drugs 0.000 title abstract 3
- 239000003472 antidiabetic agent Substances 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title abstract 3
- 230000001773 anti-convulsant effect Effects 0.000 title abstract 2
- 239000001961 anticonvulsive agent Substances 0.000 title abstract 2
- 229940125681 anticonvulsant agent Drugs 0.000 title 1
- 229960003965 antiepileptics Drugs 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
"TERAPIA DE COMBINAçãO COMPREENDENDO AGENTES ANTICONVULSANTES E ANTIDIABéTICOS". A presente invenção refere-se à terapia de combinação compreendendo agentes antidiabéticos e derivados anticonvulsantes úteis para o tratamento de diabete melitus Tipo II e Síndrome X.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24422500P | 2000-10-30 | 2000-10-30 | |
PCT/US2001/050840 WO2002064210A2 (en) | 2000-10-30 | 2001-10-25 | Combination therapy comprising anti-diabetic and anticonvulsant agents |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0115055A true BR0115055A (pt) | 2003-12-30 |
Family
ID=22921886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0115055-3A BR0115055A (pt) | 2000-10-30 | 2001-10-25 | Terapia de combinação compreendendo agentes anticonvulsantes e antidiabéticos |
Country Status (17)
Country | Link |
---|---|
US (2) | US6686337B2 (pt) |
EP (1) | EP1333887B1 (pt) |
JP (1) | JP2004518718A (pt) |
AT (1) | ATE334718T1 (pt) |
AU (1) | AU2002253838B2 (pt) |
BR (1) | BR0115055A (pt) |
CY (1) | CY1106195T1 (pt) |
DE (1) | DE60121988T2 (pt) |
DK (1) | DK1333887T3 (pt) |
ES (1) | ES2269297T3 (pt) |
MX (1) | MXPA03003870A (pt) |
NZ (1) | NZ537490A (pt) |
PT (1) | PT1333887E (pt) |
RU (1) | RU2003112618A (pt) |
TW (1) | TWI239840B (pt) |
WO (1) | WO2002064210A2 (pt) |
ZA (1) | ZA200304194B (pt) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5998256A (en) | 1996-11-01 | 1999-12-07 | Micron Technology, Inc. | Semiconductor processing methods of forming devices on a substrate, forming device arrays on a substrate, forming conductive lines on a substrate, and forming capacitor arrays on a substrate, and integrated circuitry |
US20080255093A1 (en) * | 1999-06-14 | 2008-10-16 | Tam Peter Y | Compositions and methods for treating obesity and related disorders |
US7674776B2 (en) | 1999-06-14 | 2010-03-09 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
US20080103179A1 (en) * | 2006-10-27 | 2008-05-01 | Tam Peter Y | Combination Therapy |
DE60233655D1 (de) * | 2001-04-04 | 2009-10-22 | Ortho Mcneil Janssen Pharm | R und retinoid x rezeptorenmodulatoren |
CA2442917C (en) * | 2001-04-04 | 2011-02-01 | Ortho-Mcneil Pharmaceutical, Inc. | Combination therapy comprising glucose reabsorption inhibitors and ppar modulators |
EP2301537A1 (en) * | 2002-05-17 | 2011-03-30 | Duke University | Zonisamide for the treatment of obesity |
US20040077679A1 (en) * | 2002-07-29 | 2004-04-22 | Cincotta Anthony H. | Therapeutic treatment for the metabolic syndrome and type 2 diabetes |
JP4887139B2 (ja) * | 2003-03-25 | 2012-02-29 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼインヒビター |
SI2316456T1 (sl) * | 2003-04-29 | 2017-10-30 | Orexigen Therapeutics, Inc. | Sestavki za vplivanje na izgubo teže, ki obsegajo opioidni antagonist in bupropion |
JP2007511467A (ja) | 2003-05-14 | 2007-05-10 | タケダ サン ディエゴ インコーポレイテッド | ジペプチジルペプチダーゼインヒビター |
EP1558220B1 (en) * | 2003-07-24 | 2010-02-10 | Wockhardt Limited | Oral compositions for treatment of diabetes |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
RU2006107553A (ru) * | 2003-08-13 | 2007-09-20 | Такеда Фармасьютикал Компани Лимитед (Jp) | Производные 4-пиримидона и их применение в качестве ингибиторов пептидилпептидаз |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
EP1699777B1 (en) | 2003-09-08 | 2012-12-12 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US20050065144A1 (en) * | 2003-09-08 | 2005-03-24 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
WO2005070461A2 (en) * | 2004-01-13 | 2005-08-04 | Duke University | Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss |
US7713959B2 (en) * | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
NZ549716A (en) | 2004-03-15 | 2010-04-30 | Takeda Pharmaceutical | Pyrimidin-dione derivatives as dipeptidyl peptidase inhibitors |
CN1968692A (zh) * | 2004-05-03 | 2007-05-23 | 杜克大学 | 影响体重减轻的组合物 |
WO2005118555A1 (en) | 2004-06-04 | 2005-12-15 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
EP1814590B2 (en) * | 2004-11-01 | 2013-12-11 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
US8394765B2 (en) * | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
WO2006068978A2 (en) | 2004-12-21 | 2006-06-29 | Takeda Pharmaceutial Company Limited | Dipeptidyl peptidase inhibitors |
AU2006278575A1 (en) * | 2005-08-04 | 2007-02-15 | Merck & Co., Inc. | Aminoethane sulfonamide orexin receptor antagonists |
US20090257903A1 (en) * | 2005-09-08 | 2009-10-15 | Stefan Sundin | Powder Metallurgically Manufactured High Speed Steel |
NZ566799A (en) | 2005-09-14 | 2011-04-29 | Takeda Pharmaceutical | Dipeptidyl peptidase inhibitors for treating diabetes |
PE20070622A1 (es) * | 2005-09-14 | 2007-08-22 | Takeda Pharmaceutical | Administracion de inhibidores de dipeptidil peptidasa |
PE20070458A1 (es) * | 2005-09-14 | 2007-07-05 | Takeda Pharmaceutical | Composicion farmaceutica que comprende 2-[[6-(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo como inhibidor de dipeptidil peptidasa |
TW200745079A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
CN101360723A (zh) | 2005-09-16 | 2009-02-04 | 武田药品工业株式会社 | 制备嘧啶二酮衍生物的方法 |
TW200745080A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor |
EP2135603B1 (en) * | 2005-11-22 | 2013-01-02 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
EP1999108A1 (en) * | 2006-03-28 | 2008-12-10 | Takeda Pharmaceutical Company Limited | Preparation of (r)-3-aminopiperidine dihydrochloride |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
US9744137B2 (en) * | 2006-08-31 | 2017-08-29 | Supernus Pharmaceuticals, Inc. | Topiramate compositions and methods of enhancing its bioavailability |
KR20090088854A (ko) * | 2006-09-13 | 2009-08-20 | 다케다 야쿠힌 고교 가부시키가이샤 | 2-6-(3-아미노-피페리딘-엘-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2h-피리미딘-1-일메틸-4-플루오로-벤조니트릴의 용도 |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
KR101735466B1 (ko) | 2006-11-09 | 2017-05-15 | 오렉시젠 세러퓨틱스 인크. | 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형 |
KR20150082689A (ko) * | 2006-11-09 | 2015-07-15 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
US8298576B2 (en) | 2006-11-17 | 2012-10-30 | Supernus Pharmaceuticals, Inc. | Sustained-release formulations of topiramate |
TW200838536A (en) * | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
MX2009003911A (es) * | 2006-12-04 | 2009-05-28 | Supernus Pharmaceuticals Inc | Formulaciones de liberacion inmediata, mejoradas de topiramato. |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
US11241420B2 (en) * | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US20090076128A1 (en) * | 2007-09-15 | 2009-03-19 | Protia Llc | Deuterium-enriched topiramate |
BRPI0722276A2 (pt) * | 2007-11-14 | 2014-04-22 | Amylin Pharmaceuticals Inc | Métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade |
KR101512386B1 (ko) * | 2008-04-08 | 2015-04-17 | 제이더블유중외제약 주식회사 | 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법 |
CA2725930A1 (en) * | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
US20090304789A1 (en) | 2008-06-09 | 2009-12-10 | Thomas Najarian | Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders |
US8580298B2 (en) | 2008-06-09 | 2013-11-12 | Vivus, Inc. | Low dose topiramate/phentermine composition and methods of use thereof |
WO2010045416A2 (en) * | 2008-10-16 | 2010-04-22 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
WO2010045417A2 (en) * | 2008-10-16 | 2010-04-22 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
US20100113581A1 (en) * | 2008-10-16 | 2010-05-06 | Aronne Louis J | Combination therapies for the treatment of obesity |
WO2010045522A2 (en) * | 2008-10-16 | 2010-04-22 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
US20100113604A1 (en) * | 2008-10-16 | 2010-05-06 | Aronne Louis J | Combination therapies for the treatment of obesity |
US20100331419A1 (en) * | 2009-06-25 | 2010-12-30 | Aronne Louis J | Combination Therapies for the Treatment of Obesity |
US20100331420A1 (en) * | 2009-06-26 | 2010-12-30 | Aronne Louis J | Combination Therapies for the Treatment of Obesity |
US20100331999A1 (en) * | 2009-06-29 | 2010-12-30 | Aronne Louis J | Combination Therapies for the Treatment of Obesity |
US20110015663A1 (en) * | 2009-07-17 | 2011-01-20 | Aronne Louis J | Combination Therapies for the Treatment of Obesity |
WO2011041632A2 (en) * | 2009-10-01 | 2011-04-07 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
CN102724878A (zh) * | 2010-01-11 | 2012-10-10 | 奥雷西根治疗公司 | 在重度抑郁症患者中提供体重减轻疗法的方法 |
DK3730132T3 (da) | 2012-06-06 | 2022-08-08 | Nalpropion Pharmaceuticals Llc | Sammensætning til anvendelse ved en fremgangsmåde til behandling af overvægt og obesitas hos patienter med høj kardiovaskulær risiko |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
KR101591357B1 (ko) | 2015-03-24 | 2016-02-04 | 제이더블유중외제약 주식회사 | 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4513006A (en) | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
IL103172A (en) | 1991-09-19 | 1997-01-10 | Mcneilab Inc | Preparation of chlorosulfate and sulfamate derivatives of 2, 3:4, 5-bis-o-(1-methylethylidene)-beta-d-fructopyranose and (1-methylcyclohexyl) methanol |
US5242942A (en) | 1992-04-28 | 1993-09-07 | Mcneilab, Inc. | Anticonvulsant fructopyranose cyclic sulfites and sulfates |
US5384327A (en) | 1992-12-22 | 1995-01-24 | Mcneilab, Inc. | Anticonvulsant sorbopyranose sulfamates |
US6046222A (en) * | 1993-09-15 | 2000-04-04 | Warner-Lambert Company | Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
CN1106193C (zh) * | 1996-06-28 | 2003-04-23 | 奥索·麦克尼尔药品公司 | 抗惊厥剂氨基磺酸酯衍生物用于治疗肥胖的用途 |
UA65607C2 (uk) | 1998-03-04 | 2004-04-15 | Орто-Макнейл Фармацевтикал, Інк. | Фармацевтична композиція (варіанти) та спосіб її приготування |
JP2002537326A (ja) | 1999-02-24 | 2002-11-05 | ユニヴァーシティ・オブ・シンシナティ | 衝動調節障害の治療のためのスルファメート誘導体の使用 |
US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
MXPA01010218A (es) | 1999-04-08 | 2002-03-27 | Johnson & Johnson | Derivados anticonvulsivos utiles para disminuir lipidos. |
NZ514811A (en) | 1999-04-08 | 2005-01-28 | Ortho Mcneil Pharm Inc | Anticonvulsant derivatives useful in reducing blood glucose levels |
JP2003530300A (ja) | 1999-04-08 | 2003-10-14 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 体重低下を維持することに有用な抗痙攣薬誘導体 |
ATE369126T1 (de) * | 1999-06-14 | 2007-08-15 | Vivus Inc | Kombinationstherapie zur gewichtsreduzierung und fettleibigkeitsbehandlung |
PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
-
2001
- 2001-10-25 ES ES01270165T patent/ES2269297T3/es not_active Expired - Lifetime
- 2001-10-25 AT AT01270165T patent/ATE334718T1/de active
- 2001-10-25 PT PT01270165T patent/PT1333887E/pt unknown
- 2001-10-25 JP JP2002564002A patent/JP2004518718A/ja active Pending
- 2001-10-25 RU RU2003112618/14A patent/RU2003112618A/ru not_active Application Discontinuation
- 2001-10-25 AU AU2002253838A patent/AU2002253838B2/en not_active Ceased
- 2001-10-25 DE DE60121988T patent/DE60121988T2/de not_active Expired - Lifetime
- 2001-10-25 EP EP01270165A patent/EP1333887B1/en not_active Expired - Lifetime
- 2001-10-25 BR BR0115055-3A patent/BR0115055A/pt not_active IP Right Cessation
- 2001-10-25 US US10/042,425 patent/US6686337B2/en not_active Expired - Lifetime
- 2001-10-25 DK DK01270165T patent/DK1333887T3/da active
- 2001-10-25 MX MXPA03003870A patent/MXPA03003870A/es active IP Right Grant
- 2001-10-25 WO PCT/US2001/050840 patent/WO2002064210A2/en active IP Right Grant
- 2001-10-25 NZ NZ537490A patent/NZ537490A/en unknown
- 2001-10-30 TW TW090126821A patent/TWI239840B/zh not_active IP Right Cessation
-
2003
- 2003-05-29 ZA ZA200304194A patent/ZA200304194B/en unknown
-
2004
- 2004-01-23 US US10/764,424 patent/US20040157785A1/en not_active Abandoned
-
2006
- 2006-10-12 CY CY20061101467T patent/CY1106195T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200304194B (en) | 2004-08-30 |
WO2002064210A2 (en) | 2002-08-22 |
AU2002253838B2 (en) | 2006-11-09 |
CY1106195T1 (el) | 2011-06-08 |
JP2004518718A (ja) | 2004-06-24 |
US6686337B2 (en) | 2004-02-03 |
RU2003112618A (ru) | 2004-09-27 |
PT1333887E (pt) | 2006-10-31 |
EP1333887A2 (en) | 2003-08-13 |
EP1333887B1 (en) | 2006-08-02 |
DE60121988D1 (de) | 2006-09-14 |
NZ537490A (en) | 2006-11-30 |
ES2269297T3 (es) | 2007-04-01 |
WO2002064210A3 (en) | 2003-03-06 |
TWI239840B (en) | 2005-09-21 |
US20020147157A1 (en) | 2002-10-10 |
DE60121988T2 (de) | 2007-02-15 |
ATE334718T1 (de) | 2006-08-15 |
DK1333887T3 (da) | 2006-11-13 |
MXPA03003870A (es) | 2004-08-12 |
US20040157785A1 (en) | 2004-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0115055A (pt) | Terapia de combinação compreendendo agentes anticonvulsantes e antidiabéticos | |
BR0112519A (pt) | Derivados anticonvulsivantes úteis para prevenir o desenvolvimento de diabetes melito do tipo ii e sìndrome x | |
BR9812325A (pt) | Novo uso para budesonida e formoterol | |
BR0213079A (pt) | Forma de dosagem para o tratamento da diabetes mellitus | |
DE69614332T2 (de) | Biegemechanismus und Stereoskop, der diesen verwendet | |
ATE141131T1 (de) | Fungizide wirkstoffkombinationen | |
PT825861E (pt) | Tripicolinato cromico em doses elevadas para o tratamento de diabetes de tipo ii | |
BR0015992A (pt) | Compostos, utilização dos mesmos, e, associações terapêuticas | |
EE05260B1 (et) | Metformiini ja glburiidi kombinatsiooni vikese annuse kasutamine 2. tpi suhkrut?ve esimese rea raviks | |
BR0215027A (pt) | Derivados de 6-aminomorfinano, processo de preparação para o mesmo e sua aplicação | |
BR9807655A (pt) | Uso de inibidores de lipase gastrintestinal. | |
BR0113590A (pt) | 7-oxo-piridopirimidinas | |
ES2177024T3 (es) | Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer. | |
IS5951A (is) | 5HT1 mótlyf fyrir meðferð gegn þunglyndi | |
ES2134313T3 (es) | Utilizacion de derivados de pregnano para el tratamiento de tumores. | |
BR9814495A (pt) | Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo | |
BR9912816A (pt) | Composição terapêutica à base de flavonóides, tencionada para uso no tratamento de tumores por agentes citotóxicos | |
DE69722610D1 (de) | Neue Inhalationspräparate enthaltend CR 2039 (Andolast) | |
BR0211223A (pt) | Derivados de 4-aminociclohexanol substituìdos | |
BR0007183A (pt) | Isonipectoamidas para o tratamento de distúrbios mediados por integrina | |
BR9810387A (pt) | (s) 3, 4, 5-trimetoxibenzoato de 2-metilamino-2-fenil-n-butila, e sua aplicação para o tratamento de dor crÈnica | |
DE29701600U1 (de) | Ventilmechanismus für medizinische Anwendungen | |
PT878195E (pt) | Utilizacao de um composto 2-aroil-3-arilbenzo(b)tiofeno para a reducao de fibrinogenio | |
BR9809439A (pt) | Processos para preparação de benzotiofenos | |
BR9507732A (pt) | Composição farmacêutica para o tratamento de glaucoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: JOHNSON AND JOHNSON (US) Free format text: TRANSFERIDO DE: ORTHO-MCNEIL PHARMACEUTICAL, INC. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2021 DE 29/09/2009. |
|
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 45/06 (2006.01), A61P 3/10 (2006.01), A61K 31 |